Cohance Lifesciences Ltd
COHANCE
Company Profile
Business description
Cohance Lifesciences Ltd is a CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commercialization. Its Business Units comprise: CDMO, API+ and Formulations, and Clinical and Analytical Services.
Contact
Hitech City Road, Panmaktha Plot, 1
202, 2nd Floor, B-Wing, Galaxy by Aurobindo Realty, Sy No 83/1
Hyderabad Knowledge City TSIIC Raidurg
Opposite IKEA
HyderabadTG500081
INDT: +91 4023549414
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2027
Employees
2,295
Stocks News & Analysis
stocks
Chart of the Week: Recent selloffs in this ASX sector opens doors to opportunity
Ongoing rate hikes have investors spooked.
stocks
ASX dividend champions: Stocks, ETFs and LICs
Mark and Shani run through lessons for ASX stocks, ETFs and LICs that have delivered over the past decade.
stocks
SpaceX’s IPO filing: Big spending, big losses
The first public financials from Elon Musk’s company highlight Starlink’s revenue power and increased spending on AI.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,840.80 | 9.50 | -0.11% |
| CAC 40 | 8,067.84 | 49.58 | -0.61% |
| DAX 40 | 24,563.84 | 173.40 | -0.70% |
| Dow JONES (US) | 50,009.35 | 645.47 | 1.31% |
| FTSE 100 | 10,390.90 | 41.44 | -0.40% |
| HKSE | 25,386.52 | 264.60 | -1.03% |
| NASDAQ | 26,270.36 | 399.65 | 1.54% |
| Nikkei 225 | 61,684.14 | 1,879.73 | 3.14% |
| NZX 50 Index | 12,878.07 | 117.04 | 0.92% |
| S&P 500 | 7,432.97 | 79.36 | 1.08% |
| S&P/ASX 200 | 8,621.70 | 6.30 | -0.07% |
| SSE Composite Index | 4,077.28 | 84.91 | -2.04% |